statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Bitcoin

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Invesco QQQ Trust Series 1

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Seres Therapeutics, Inc. (Nasdaq: MCRB), a leading microbiome therapeutics company, announced today that enrollment is complete in the placebo-controlled Cohort 2 of its Phase 1b trial of SER-155 in...

Seres Therapeutics Announces Completion of Patient Enrollment for SER-155 Phase 1B Cohort 2 Clinical Trial in Allogenic HSCT

Flagship Appoints Amy O'Shea as CEO-Partner and Chief Executive Officer of Invaio Sciences Flagship Appoints Amy O'Shea as CEO-Partner and Chief Executive Officer of Invaio Sciences PR Newswire...

Flagship Appoints Amy O'Shea as CEO-Partner and Chief Executive Officer of Invaio Sciences

Seres Therapeutics, Inc. (Nasdaq: MCRB) (Seres or the Company), a leading microbiome therapeutics company, today announced that on March 25, 2024, the Compensation and Talent Committee of Seres board...

Seres Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Flagship Pioneering Named to Fast Company's Annual List of the World's Most Innovative Companies of 2024 Flagship Pioneering Named to Fast Company's Annual List of the World's Most Innovative...

Flagship Pioneering Named to Fast Company's Annual List of the World's Most Innovative Companies of 2024

Seres Therapeutics, Inc. (Nasdaq: MCRB) (Seres or the Company), a leading microbiome therapeutics company, today announced that on March 13, 2024, the Compensation and Talent Committee of Seres board...

Key Insights Given the large stake in the stock by institutions, Seres Therapeutics' stock price might be vulnerable to...

Institutional owners may take dramatic actions as Seres Therapeutics, Inc.'s (NASDAQ:MCRB) recent 25% drop adds to one-year losses

Seres Therapeutics, Inc. (Nasdaq: MCRB), a leading microbiome therapeutics company, today announced that management will host a conference call and live audio webcast on March 5, 2024 at 8:30 a.m. ET...

Seres Therapeutics to Host Fourth Quarter 2023 Financial Results and Operational Progress Conference Call and Webcast on March 5, 2024

Seres Therapeutics, Inc. (Nasdaq: MCRB), a leading microbiome therapeutics company, announced today that Eric Shaff, President and Chief Executive Officer of Seres Therapeutics, will participate in a...

Seres Therapeutics to Participate in Cowen 44th Annual Healthcare Conference

Seres Therapeutics names Marella Thorell as CFO...

Seres Therapeutics names Marella Thorell as CFO

Seres Therapeutics, Inc. (Nasdaq: MCRB), a leading microbiome therapeutics company, announced today that Marella Thorell will join as Executive Vice President and Chief Financial Officer (CFO), as of...

Seres Therapeutics Announces the Appointment of Marella Thorell as Chief Financial Officer and the Retirement of David Arkowitz

Seres Therapeutics, Inc. engages in the development of biological drugs through microbiome therapeutics platform. Its product pipeline includes SER-109, SER-287, SER-301, and SER-401. The company was founded by Geoffrey von Maltzahn, David A. Berry, and Noubar B. Afeyan on October 18, 2010 and is headquartered in Cambridge, MA.

Volume	4.79M
52-Wk High	$6.26
52-Wk Low	$0.54

MCRB Seres Therapeutics Inc

About

Feed

News

Sentiment

Earnings

Fundamentals